1White B. Immunopathogenesis of systemic sclerosis. Rheum Dis ClinNorth Am, 1996, 22(4) :695 -708.
2Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma. Colla-gen. Rheum Dis Clin North Am, 1996, 22(4) :647 -674.
3Dziadzio M, Denton CP, Smith R, et al. Lo6amn therapy forRaynaud's phenomenon and seleroderma: clinical and biochemicalfindings in a fifteen-week, randomized, parallel-group, controlled tri-M. Arthritis Rheum, 1999, 42(12) :2646-2655.
4Black CM, Halkier-Sorensen L, Belch JJ, et al. Oral iloprost inRaynaud ~ phenomenon secondary to systemic sclerosis: a multicentre,placebo-controlled, dose-comparison study. Br J Rheumatol, 1998,37(9) :952 -960.
5Leighton C. Drug treatment of scleroderma. Drugs, 2001, 61 (3) :419 -427.
6Furst DE, Clements PJ, Hillis S, et al. Immunesuppression withchlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum,1989, 32(5) :584 -593.
7van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison ofmethotrexate with placebo in the treatment of systemic sclerosis: a 24week randomized double-blind trial, followed by a 24 week observa-tional trial. Br J Rheumatol, 1996, 35(4) :364-372.
8Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporine in sys-temic sclerosis. Results of a forty-eight-week open safety study in tenpatients. Arthritis Rheum, 1993, 36(1) :75 -83.
9Benrud-Larson LM, Haythomthwaite JA, Heinberg Ll, et al. The im-pact of pain and symptoms of depression in scleroderma. Pain, 2002,95 (3) :267 - 275.
10Medsger TA Jr, Lucas M, Wildy KS, et al. D-penicillamine in sys-temic sclerosis? Yes! Scand J Rheumatol, 2001,30(4) :192 - 194.
